anurajms/meta_analysis huggingface dataset:
MESH terms:
Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
1. Androgen Antagonists [adverse effects, *therapeutic use]; 2. Anilides [adverse effects, therapeutic use]; 3. Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use]; 4. Disease Progression; 5. Flutamide [adverse effects, therapeutic use]; 6. Gonadotropin‐Releasing Hormone [adverse effects, *therapeutic use]; 7. Goserelin [adverse effects, therapeutic use]; 8. Leuprolide [adverse effects, therapeutic use]; 9. Medication Adherence [statistics & numerical data]; 10. Nitriles [adverse effects, therapeutic use]; 11. Orchiectomy [*methods, mortality]; 12. Prostatic Neoplasms [mortality, pathology, *therapy]; 13. Randomized Controlled Trials as Topic; 14. Tosyl Compounds [adverse effects, therapeutic use]; 15. Triptorelin Pamoate [adverse effects, therapeutic use];
MESH terms:
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain
1. Analgesics, Opioid [adverse effects, *therapeutic use]; 2. Appetite [*drug effects]; 3. Codeine [adverse effects, therapeutic use]; 4. Consciousness [*drug effects]; 5. Fentanyl [adverse effects, therapeutic use]; 6. Morphine [adverse effects, therapeutic use]; 7. Neoplasms [*complications]; 8. Oxycodone [adverse effects, therapeutic use]; 9. Pain [*drug therapy, etiology]; 10. Randomized Controlled Trials as Topic; 11. Terminal Care; 12. Thirst [*drug effects];
MESH terms:
Surgical treatment of stage IA2 cervical cancer
1. Neoplasm Staging; 2. Uterine Cervical Neoplasms [pathology, *surgery];
MESH terms:
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
1. Antineoplastic Agents, Hormonal [*therapeutic use]; 2. Breast Neoplasms [*drug therapy, *surgery]; 3. Combined Modality Therapy; 4. Randomized Controlled Trials as Topic; 5. Tamoxifen [*therapeutic use];
MESH terms:
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas
1. Astrocytoma [*drug therapy, *radiotherapy, surgery]; 2. Brain Neoplasms [*drug therapy, *radiotherapy, surgery]; 3. Chemotherapy, Adjuvant; 4. Oligodendroglioma [*drug therapy, *radiotherapy, surgery]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Adjuvant chemotherapy for advanced endometrial cancer
1. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 2. Chemoradiotherapy; 3. Chemotherapy, Adjuvant [adverse effects, methods, mortality]; 4. Cisplatin [administration & dosage]; 5. Disease-Free Survival; 6. Doxorubicin [administration & dosage]; 7. Endometrial Neoplasms [*drug therapy, mortality, pathology, therapy]; 8. Neoplasm Staging; 9. Paclitaxel [administration & dosage]; 10. Radiotherapy, Adjuvant; 11. Randomized Controlled Trials as Topic;
MESH terms:
Medically assisted nutrition for adult palliative care patients
1. *Enteral Nutrition [adverse effects, methods]; 2. *Parenteral Nutrition [adverse effects, methods]; 3. Longevity; 4. Palliative Care [*methods]; 5. Quality of Life;
MESH terms:
Laparoscopic versus open total mesorectal excision for rectal cancer
1. *Laparoscopy; 2. Conversion to Open Surgery [statistics & numerical data]; 3. Elective Surgical Procedures; 4. Rectal Neoplasms [*surgery]; 5. Rectum [*surgery]; 6. Treatment Outcome;
MESH terms:
Surgical interventions for high‐grade vulval intraepithelial neoplasia
1. Carcinoma in Situ [pathology, *surgery]; 2. Lasers, Gas [*therapeutic use]; 3. Precancerous Conditions [pathology, *surgery]; 4. Randomized Controlled Trials as Topic; 5. Suction [methods]; 6. Ultrasonic Therapy [instrumentation, *methods]; 7. Vulvar Neoplasms [pathology, *surgery];
MESH terms:
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
1. *Radiosurgery; 2. Brain Neoplasms [mortality, *radiotherapy, secondary, *surgery]; 3. Combined Modality Therapy [methods]; 4. Cranial Irradiation [*methods]; 5. Disease‐Free Survival; 6. Randomized Controlled Trials as Topic;
MESH terms:
Resection versus other treatments for locally advanced pancreatic cancer
1. Chemoradiotherapy, Adjuvant; 2. Immunotherapy [methods]; 3. Lymph Node Excision; 4. Palliative Care [*methods]; 5. Pancreas [blood supply, *surgery]; 6. Pancreatectomy [methods]; 7. Pancreatic Neoplasms [blood supply, mortality, *therapy]; 8. Pancreaticoduodenectomy [methods]; 9. Randomized Controlled Trials as Topic; 10. Splenectomy; 11. Survival Rate;
MESH terms:
De‐escalation treatment protocols for human papillomavirus‐associated oropharyngeal squamous cell carcinoma
1. Carcinoma, Squamous Cell [*therapy, *virology]; 2. Clinical Protocols; 3. Oropharyngeal Neoplasms [*therapy, *virology]; 4. Papillomavirus Infections [complications, *therapy]; 5. Prospective Studies; 6. Systematic Reviews as Topic;
MESH terms:
Exenterative surgery for recurrent gynaecological malignancies
1. Genital Neoplasms, Female [pathology, *surgery]; 2. Neoplasm Recurrence, Local [*surgery]; 3. Pelvic Exenteration;
MESH terms:
Combination versus sequential single agent chemotherapy for metastatic breast cancer
1. Antineoplastic Agents [*administration & dosage, adverse effects]; 2. Antineoplastic Combined Chemotherapy Protocols [*administration & dosage, adverse effects]; 3. Breast Neoplasms [*drug therapy, mortality, pathology]; 4. Disease Progression; 5. Disease-Free Survival; 6. Nausea [chemically induced]; 7. Neutropenia [chemically induced]; 8. Randomized Controlled Trials as Topic; 9. Vomiting [chemically induced];
MESH terms:
Chemotherapy versus best supportive care for extensive small cell lung cancer
1. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 2. Carcinoma, Small Cell [*drug therapy, mortality, pathology]; 3. Doxorubicin [administration & dosage]; 4. Lung Neoplasms [*drug therapy, mortality, pathology]; 5. Methotrexate [administration & dosage]; 6. Organoplatinum Compounds [administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Survival Analysis; 9. Topotecan [administration & dosage];
MESH terms:
Post‐operative radiotherapy for ductal carcinoma in situ of the breast
1. Breast Neoplasms [*radiotherapy, surgery]; 2. Carcinoma in Situ [*radiotherapy, surgery]; 3. Carcinoma, Ductal, Breast [*radiotherapy, surgery]; 4. Combined Modality Therapy [methods]; 5. Mastectomy, Segmental; 6. Radiotherapy [adverse effects]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Patient‐reported outcome measures for follow‐up after gynaecological cancer treatment
1. Follow-Up Studies; 2. Genital Neoplasms, Female [*therapy]; 3. *Outcome Assessment, Health Care; 4. *Self Report;
MESH terms:
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
1. Antibiotics, Antineoplastic [*therapeutic use]; 2. Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; 3. Carboplatin [administration & dosage]; 4. Carcinoma, Ovarian Epithelial; 5. Doxorubicin [*analogs & derivatives, therapeutic use]; 6. Drug Administration Schedule; 7. Neoplasms, Glandular and Epithelial [*drug therapy]; 8. Ovarian Neoplasms [*drug therapy]; 9. Paclitaxel [administration & dosage]; 10. Polyethylene Glycols [therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
1. Administration, Oral; 2. Anti-Bacterial Agents [*administration & dosage, adverse effects]; 3. Chemotherapy-Induced Febrile Neutropenia [*drug therapy, mortality]; 4. Injections, Intravenous; 5. Neoplasms [*drug therapy]; 6. Randomized Controlled Trials as Topic; 7. Treatment Failure;
MESH terms:
Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer
1. Hysterectomy [*methods]; 2. Hysterectomy, Vaginal [methods]; 3. Laparoscopy [*methods]; 4. Neoplasm Staging; 5. Randomized Controlled Trials as Topic; 6. Uterine Cervical Neoplasms [pathology, *surgery];
MESH terms:
Perioperative nutrition interventions for women with ovarian cancer
1. Elective Surgical Procedures; 2. Fluid Therapy [*methods]; 3. *Food; 4. Malnutrition [*diet therapy, etiology]; 5. Ovarian Neoplasms [complications, *surgery]; 6. Perioperative Care [*methods]; 7. Postoperative Nausea and Vomiting [epidemiology]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Cervico‐thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome
1. Catheter Ablation [*methods]; 2. Complex Regional Pain Syndromes [*therapy]; 3. Leg [innervation]; 4. Neck; 5. Neuralgia [*therapy]; 6. Phenol; 7. Randomized Controlled Trials as Topic; 8. Sympathectomy [*methods]; 9. Sympathectomy, Chemical [methods]; 10. Sympatholytics; 11. Thorax;
MESH terms:
Psychosocial interventions for patients with head and neck cancer
1. Depression [*therapy]; 2. Head and Neck Neoplasms [*psychology]; 3. *Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Stress, Psychological [*therapy]; 6. Surveys and Questionnaires;
MESH terms:
Maintenance chemotherapy for ovarian cancer
1. Antineoplastic Agents [*therapeutic use]; 2. Disease-Free Survival; 3. Maintenance Chemotherapy [adverse effects, *methods]; 4. Ovarian Neoplasms [*drug therapy, mortality, radiotherapy]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia
1. Aminoglycosides [adverse effects, *therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Cause of Death; 4. Combined Modality Therapy [adverse effects, methods]; 5. Neoplasms [*complications]; 6. Neutropenia [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic; 8. beta‐Lactams [*therapeutic use];
MESH terms:
Interventions for cutaneous Bowen's disease
1. *Cryotherapy; 2. *Neoplasm Recurrence, Local; 3. Aminolevulinic Acid [analogs & derivatives, therapeutic use]; 4. Aminoquinolines [therapeutic use]; 5. Antineoplastic Agents [*therapeutic use]; 6. Bowen's Disease [*therapy]; 7. Fluorouracil [therapeutic use]; 8. Imiquimod; 9. Photochemotherapy [*methods]; 10. Photosensitizing Agents [*therapeutic use]; 11. Skin Neoplasms [*therapy]; 12. Treatment Outcome;
MESH terms:
Interferon alpha for the adjuvant treatment of cutaneous melanoma
1. Antineoplastic Agents [*therapeutic use]; 2. Chemotherapy, Adjuvant [methods, mortality]; 3. Disease‐Free Survival; 4. Interferon‐alpha [*therapeutic use]; 5. Melanoma [*drug therapy, mortality, surgery]; 6. Randomized Controlled Trials as Topic; 7. Skin Neoplasms [*drug therapy, mortality, surgery];
MESH terms:
Effectiveness and cost‐effectiveness of home palliative care services for adults with advanced illness and their caregivers
1. Attitude to Death; 2. *Caregivers; 3. Cost-Benefit Analysis; 4. Critical Illness [*nursing]; 5. *Home Care Services [economics]; 6. Palliative Care [economics, *methods]; 7. Patient Preference; 8. Randomized Controlled Trials as Topic; 9. Treatment Outcome;
MESH terms:
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
1. Antineoplastic Agents [adverse effects, *therapeutic use]; 2. Carcinoma, Ovarian Epithelial; 3. Disease‐Free Survival; 4. Interferons [adverse effects, *therapeutic use]; 5. Neoplasms, Glandular and Epithelial [*drug therapy, mortality, pathology, surgery]; 6. Ovarian Neoplasms [*drug therapy, mortality, pathology, surgery];
MESH terms:
Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary surgery
1. Axilla; 2. Breast Neoplasms [*surgery]; 3. Fibrin Tissue Adhesive [*administration & dosage]; 4. Hemostatics [*administration & dosage]; 5. Lymph Node Excision [*adverse effects]; 6. Postoperative Complications [*prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Seroma [*prevention & control]; 9. *Surgical Flaps; 10. Treatment Failure;
MESH terms:
Sequencing of chemotherapy and radiotherapy for early breast cancer
1. Anemia [etiology]; 2. Breast Neoplasms [*drug therapy, mortality, *radiotherapy, surgery]; 3. Chemotherapy, Adjuvant [adverse effects, *methods]; 4. Pigmentation Disorders [etiology]; 5. Radiotherapy, Adjuvant [adverse effects, *methods]; 6. Randomized Controlled Trials as Topic; 7. Telangiectasis [etiology]; 8. Time Factors;
MESH terms:
Temozolomide for high grade glioma
1. Age Factors; 2. Antineoplastic Agents, Alkylating [*therapeutic use]; 3. Brain Neoplasms [*drug therapy, pathology, radiotherapy]; 4. Dacarbazine [*analogs & derivatives, therapeutic use]; 5. Glioblastoma [*drug therapy, pathology, radiotherapy]; 6. Neoplasm Grading; 7. Neoplasm Recurrence, Local [drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Survival Analysis; 10. Temozolomide;
MESH terms:
Megestrol acetate for treatment of anorexia‐cachexia syndrome
1. Acquired Immunodeficiency Syndrome [complications]; 2. Anorexia [*drug therapy, etiology]; 3. Appetite Stimulants [adverse effects, *therapeutic use]; 4. Cachexia [*drug therapy, etiology]; 5. Megestrol Acetate [adverse effects, *therapeutic use]; 6. Neoplasms [complications]; 7. Randomized Controlled Trials as Topic; 8. Syndrome;
MESH terms:
Pre‐treatment surgical para‐aortic lymph node assessment in locally advanced cervical cancer
1. Aorta, Abdominal; 2. Disease-Free Survival; 3. Lymph Node Excision [adverse effects]; 4. Lymph Nodes [*pathology, surgery]; 5. Lymphatic Metastasis; 6. Magnetic Resonance Imaging; 7. Neoplasm Staging [*methods]; 8. Randomized Controlled Trials as Topic; 9. Tomography, X-Ray Computed; 10. Uterine Cervical Neoplasms [*pathology, radiotherapy, surgery];
MESH terms:
Multidimensional rehabilitation programmes for adult cancer survivors
1. *Health Status; 2. *Program Evaluation; 3. *Survivors [psychology]; 4. Neoplasms [psychology, *rehabilitation]; 5. Randomized Controlled Trials as Topic; 6. Treatment Outcome;
MESH terms:
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma
1. Antineoplastic Agents, Alkylating [therapeutic use]; 2. Carcinosarcoma [*drug therapy, mortality, *radiotherapy, surgery]; 3. Chemotherapy, Adjuvant; 4. Ifosfamide [therapeutic use]; 5. Paclitaxel [therapeutic use]; 6. Radiotherapy [adverse effects, methods]; 7. Radiotherapy, Adjuvant; 8. Randomized Controlled Trials as Topic; 9. Uterine Neoplasms [*drug therapy, mortality, *radiotherapy, surgery];
MESH terms:
Chemotherapy for metastatic and recurrent cervical cancer
1. Age Factors; 2. Antineoplastic Agents [administration & dosage, adverse effects]; 3. Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; 4. Cisplatin [administration & dosage, adverse effects]; 5. Neoplasm Recurrence, Local [*drug therapy]; 6. Paclitaxel [administration & dosage]; 7. Uterine Cervical Neoplasms [*drug therapy, pathology];
MESH terms:
Interventions for reducing anxiety in women undergoing colposcopy
1. Anxiety [*prevention & control]; 2. Colposcopy [adverse effects, *psychology]; 3. Microscopy, Video; 4. Music Therapy; 5. Pain [etiology]; 6. Pain Measurement [methods]; 7. Pamphlets; 8. Patient Education as Topic; 9. Randomized Controlled Trials as Topic; 10. Uterine Cervical Neoplasms [diagnosis, psychology];
MESH terms:
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
1. Neoplasm Recurrence, Local [*drug therapy, pathology]; 2. Neoplasm Staging; 3. Neoplasms, Germ Cell and Embryonal [*drug therapy, pathology]; 4. Ovarian Neoplasms [*drug therapy, pathology]; 5. Randomized Controlled Trials as Topic; 6. Retrospective Studies;
MESH terms:
Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
1. Carcinoma, Non‐Small‐Cell Lung [*drug therapy, mortality, *surgery]; 2. Chemotherapy, Adjuvant; 3. Lung Neoplasms [*drug therapy, mortality, *surgery]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Topical anti‐inflammatory treatments for eczema: network meta‐analysis
1. Administration, Topical; 2. Adrenal Cortex Hormones [administration & dosage, therapeutic use]; 3. *Anti-Inflammatory Agents [administration & dosage, therapeutic use]; 4. Bias; 5. *Eczema [drug therapy]; 6. Emollients [therapeutic use]; 7. *Network Meta-Analysis; 8. Quality of Life; 9. *Randomized Controlled Trials as Topic;
MESH terms:
Non‐invasive high‐frequency ventilation in newborn infants with respiratory distress
1. Bias; 2. *High-Frequency Ventilation [methods]; 3. *Infant, Premature; 4. Intubation, Intratracheal [methods]; 5. *Noninvasive Ventilation [methods]; 6. Pulmonary Surfactants [therapeutic use]; 7. *Randomized Controlled Trials as Topic; 8. *Respiratory Distress Syndrome, Newborn [mortality, therapy];
MESH terms:
Oral killed cholera vaccines for preventing cholera
1. Bangladesh; 2. *Cholera [prevention & control]; 3. *Cholera Vaccines; 4. Diarrhea; 5. Vaccination; 6. Vaccines, Inactivated [adverse effects];
MESH terms:
Topical and oral steroids for otitis media with effusion (OME) in children
1. Administration, Intranasal; 2. Adrenal Cortex Hormones [therapeutic use]; 3. *Anti-Bacterial Agents [therapeutic use]; 4. *Otitis Media with Effusion [drug therapy]; 5. Steroids [adverse effects];
MESH terms:
Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries
1. *Developing Countries; 2. Health Education; 3. Immunization; 4. Randomized Controlled Trials as Topic; 5. Vaccination; 6. *Vaccines;
MESH terms:
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
1. Aminophenols [adverse effects]; 2. *Cystic Fibrosis [drug therapy, genetics]; 3. Cystic Fibrosis Transmembrane Conductance Regulator [genetics]; 4. Dyspnea [drug therapy]; 5. Mutation;
MESH terms:
Different antibiotic treatments for group A streptococcal pharyngitis
1. Amoxicillin [adverse effects]; 2. Anti-Bacterial Agents [adverse effects]; 3. *Azithromycin [adverse effects]; 4. Cephalosporins [adverse effects]; 5. Chronic Disease; 6. Macrolides [adverse effects]; 7. Penicillins [adverse effects]; 8. *Pharyngitis [drug therapy]; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Streptococcus pyogenes; 12. Systematic Reviews as Topic;
MESH terms:
Ventilation tubes (grommets) for otitis media with effusion (OME) in children
1. Anti-Bacterial Agents [therapeutic use]; 2. *Hearing Loss; 3. Neoplasm Recurrence, Local [drug therapy]; 4. *Otitis Media with Effusion [etiology]; 5. *Tympanic Membrane Perforation [complications, drug therapy];
MESH terms:
Antibiotics for acute otitis media in children
1. Acute Disease; 2. Anti-Bacterial Agents [adverse effects]; 3. Diarrhea [chemically induced]; 4. *Exanthema; 5. *Otitis Media [drug therapy, epidemiology]; 6. Pain [drug therapy]; 7. *Tympanic Membrane Perforation [chemically induced, drug therapy]; 8. Vomiting [chemically induced];
MESH terms:
Methylxanthine for the prevention and treatment of apnea in preterm infants
1. Apnea [drug therapy, prevention & control]; 2. Caffeine [therapeutic use]; 3. *Cerebral Palsy; 4. *Disabled Persons; 5. Infant, Premature; 6. *Lung Diseases; 7. *Motor Disorders; 8. Oxygen;
MESH terms:
Anti‐seizure medications for neonates with seizures
1. *Epilepsy [drug therapy]; 2. Levetiracetam [therapeutic use]; 3. Phenobarbital [therapeutic use]; 4. *Phenytoin [therapeutic use]; 5. Seizures [drug therapy];
MESH terms:
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
1. Adrenal Cortex Hormones [therapeutic use]; 2. Hospitalization; 3. Oxygen; 4. *Respiratory Syncytial Virus Infections [drug therapy]; 5. *Respiratory Tract Infections;
MESH terms:
Immunomodulatory interventions for focal epilepsy
1. Anticonvulsants [adverse effects]; 2. *Drug Resistant Epilepsy [drug therapy]; 3. Drug Therapy, Combination; 4. *Drug-Related Side Effects and Adverse Reactions; 5. *Epilepsies, Partial [chemically induced, drug therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Seizures [drug therapy];
MESH terms:
Higher versus lower sodium intake for preterm infants
1. *Enterocolitis, Necrotizing [epidemiology, prevention & control]; 2. Growth Disorders; 3. *Hypernatremia [epidemiology, etiology]; 4. *Hyponatremia [epidemiology, etiology]; 5. Infant, Premature; 6. *Lung Diseases; 7. Sodium; 8. *Sodium, Dietary [adverse effects];
MESH terms:
Superoxide dismutase for bronchopulmonary dysplasia in preterm infants
1. *Bronchopulmonary Dysplasia [prevention & control]; 2. Infant, Premature; 3. Oxygen; 4. Randomized Controlled Trials as Topic; 5. *Retinopathy of Prematurity [prevention & control]; 6. Superoxide Dismutase [therapeutic use];
MESH terms:
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants
1. Aminophylline [therapeutic use]; 2. Apnea [drug therapy, prevention & control]; 3. Birth Weight; 4. *Bronchopulmonary Dysplasia [prevention & control]; 5. Caffeine [therapeutic use]; 6. *Hearing Loss; 7. Infant, Extremely Premature; 8. Randomized Controlled Trials as Topic; 9. Theophylline [therapeutic use];
MESH terms:
Psychological interventions for depression in adolescent and adult congenital heart disease
1. *Cognitive Behavioral Therapy [methods]; 2. Depression [therapy]; 3. *Heart Defects, Congenital [complications]; 4. Psychosocial Intervention; 5. Psychotherapy [methods]; 6. Quality of Life;
MESH terms:
Musical and vocal interventions to improve neurodevelopmental outcomes for preterm infants
1. *Drug-Related Side Effects and Adverse Reactions; 2. Gestational Age; 3. Infant, Premature; 4. *Music; 5. *Premature Birth; 6. Quality of Life;
MESH terms:
Breastfeeding or breast milk for procedural pain in neonates
1. Acetaminophen [therapeutic use]; 2. Breast Feeding; 3. *Milk, Human; 4. Pain [etiology, prevention & control]; 5. *Pain, Procedural [prevention & control];
MESH terms:
Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa
1. *Anorexia Nervosa [therapy]; 2. *Antipsychotic Agents; 3. *Cognitive Behavioral Therapy; 4. *Drug-Related Side Effects and Adverse Reactions; 5. Fear;
MESH terms:
Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
1. *Acetaminophen [therapeutic use]; 2. Anti-Bacterial Agents; 3. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 4. Fever [drug therapy]; 5. Ibuprofen [therapeutic use]; 6. *Otitis Media [complications, drug therapy]; 7. Pain;
MESH terms:
High flow nasal cannula for respiratory support in term infants
1. *Cannula; 2. Continuous Positive Airway Pressure [adverse effects]; 3. *Lung Diseases [etiology]; 4. Oxygen; 5. Respiration, Artificial;
MESH terms:
Vocabulary interventions for second language (L2) learners up to six years of age
1. Cognition; 2. *Communication; 3. Emotions; 4. Language; 5. *Vocabulary;
MESH terms:
Perioperative glycaemic control for people with diabetes undergoing surgery
1. Blood Glucose [analysis]; 2. *Cardiovascular Diseases; 3. *Diabetes Mellitus, Type 2 [complications]; 4. Glycemic Control; 5. *Hypoglycemia [chemically induced]; 6. Hypoglycemic Agents [therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. *Enterocolitis, Necrotizing [epidemiology]; 2. Fetal Growth Retardation; 3. Infant, Extremely Premature; 4. *Infant, Premature, Diseases [etiology, prevention & control]; 5. Infant, Very Low Birth Weight; 6. *Probiotics;
MESH terms:
Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants
1. Continuous Positive Airway Pressure [adverse effects, methods]; 2. Infant, Extremely Premature; 3. Intermittent Positive-Pressure Ventilation [adverse effects]; 4. Oxygen; 5. *Pneumothorax [epidemiology, etiology, prevention & control]; 6. *Respiratory Distress Syndrome, Newborn [therapy]; 7. *Respiratory Insufficiency [therapy];
MESH terms:
Continuous positive airway pressure (CPAP) for apnoea of prematurity
1. *Continuous Positive Airway Pressure; 2. *Drug-Related Side Effects and Adverse Reactions; 3. Dyspnea; 4. Infant, Premature; 5. Respiration; 6. Respiration, Artificial;
MESH terms:
Vedolizumab for induction and maintenance of remission in Crohn's disease
1. Antibodies, Monoclonal, Humanized [adverse effects]; 2. *Colitis, Ulcerative [drug therapy]; 3. *Crohn Disease [drug therapy, surgery]; 4. *Inflammatory Bowel Diseases [drug therapy]; 5. Remission Induction;
MESH terms:
Mobile phone‐based interventions for improving contraception use
1. *Cell Phone; 2. Communication; 3. Contraception; 4. Randomized Controlled Trials as Topic; 5. Telephone; 6. *Text Messaging;
MESH terms:
Infant isolation and cohorting for preventing or reducing transmission of healthcare‐associated infections in neonatal units
1. *Cross Infection [prevention & control]; 2. Delivery of Health Care; 3. Infant Mortality; 4. Intensive Care Units, Neonatal; 5. Patient Isolation;
MESH terms:
Oral contraceptives containing drospirenone for premenstrual syndrome
1. Contraceptives, Oral, Combined [adverse effects]; 2. *Drug-Related Side Effects and Adverse Reactions; 3. Estrogens [therapeutic use]; 4. *Premenstrual Dysphoric Disorder; 5. *Premenstrual Syndrome [drug therapy]; 6. Progestins [therapeutic use];
MESH terms:
Opioids for procedural pain in neonates
1. Analgesics [therapeutic use]; 2. Analgesics, Opioid [adverse effects]; 3. Apnea; 4. Bradycardia; 5. Fentanyl [adverse effects]; 6. *Hypotension; 7. Morphine [adverse effects]; 8. Pain [drug therapy, etiology]; 9. *Pain, Procedural [drug therapy, prevention & control];
MESH terms:
Oral stimulation for promoting oral feeding in preterm infants
1. *COVID-19; 2. Enteral Nutrition; 3. Infant, Premature; 4. Intensive Care Units, Neonatal;
MESH terms:
Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates
1. Anti-Bacterial Agents [adverse effects]; 2. *Enterocolitis, Necrotizing [drug therapy]; 3. Immunoglobulin M; 4. Immunoglobulins, Intravenous [therapeutic use]; 5. Infant, Premature; 6. *Lung Diseases; 7. *Neonatal Sepsis [drug therapy]; 8. *Pentoxifylline [adverse effects]; 9. *Retinopathy of Prematurity; 10. *Sepsis [drug therapy];
MESH terms:
Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants
1. Birth Weight; 2. *Enterocolitis, Necrotizing [epidemiology, etiology, prevention & control]; 3. Infant, Premature; 4. *Infant, Premature, Diseases [etiology, prevention & control]; 5. *Infections;
MESH terms:
Nebulised hypertonic saline for cystic fibrosis
1. Administration, Inhalation; 2. Amiloride [therapeutic use]; 3. *Cystic Fibrosis [drug therapy]; 4. Mannitol [therapeutic use]; 5. Saline Solution, Hypertonic [therapeutic use]; 6. Sodium; 7. Xylitol [therapeutic use];
MESH terms:
Non‐pharmacological management of infant and young child procedural pain
1. *Acute Pain [therapy]; 2. Blood Specimen Collection; 3. Pain Management; 4. *Pain, Procedural [therapy]; 5. Systematic Reviews as Topic;
MESH terms:
Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive pregnant women co‐infected with hepatitis B virus
1. Antiviral Agents; 2. *Coinfection; 3. DNA, Viral; 4. Emtricitabine; 5. Hepatitis B e Antigens; 6. Hepatitis B virus; 7. HIV; 8. *HIV Infections; 9. *HIV Seropositivity; 10. Infectious Disease Transmission, Vertical; 11. Lamivudine; 12. Lopinavir; 13. Pregnant Women; 14. Ritonavir; 15. Tenofovir; 16. Zidovudine;
MESH terms:
Hand hygiene for the prevention of infections in neonates
1. *Anti-Infective Agents, Local [therapeutic use]; 2. Ethanol; 3. *Hand Hygiene; 4. *Perinatal Death; 5. Soaps;
MESH terms:
Comparative effectiveness of psychological interventions for treating the psychological consequences of sexual abuse in children and adolescents: a network meta‐analysis
1. *Cognitive Behavioral Therapy [methods]; 2. Network Meta-Analysis; 3. Psychosocial Intervention; 4. Psychotherapy [methods]; 5. *Sex Offenses;
MESH terms:
Alemtuzumab for multiple sclerosis
1. Alemtuzumab [adverse effects]; 2. Interferon beta-1a [adverse effects]; 3. *Multiple Sclerosis [drug therapy]; 4. *Multiple Sclerosis, Relapsing-Remitting [drug therapy]; 5. Neoplasm Recurrence, Local [drug therapy];
MESH terms:
Interventions for the symptoms and signs resulting from jellyfish stings
1. *Acetic Acid; 2. *Ammonia; 3. Pain;
MESH terms:
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
1. Anti-Bacterial Agents [therapeutic use]; 2. Azithromycin [therapeutic use]; 3. Ceftazidime [therapeutic use]; 4. Ciprofloxacin [therapeutic use]; 5. Colistin [therapeutic use]; 6. *Cystic Fibrosis [complications, drug therapy]; 7. Monobactams [therapeutic use]; 8. Pseudomonas aeruginosa; 9. *Pseudomonas Infections [complications, drug therapy]; 10. Tobramycin [therapeutic use];
MESH terms:
Acetylcholinesterase inhibitors for autistic spectrum disorders
1. Acetylcholine; 2. *Autism Spectrum Disorder [drug therapy]; 3. Cholinesterase Inhibitors [adverse effects]; 4. Donepezil [adverse effects]; 5. Galantamine [adverse effects]; 6. *Risperidone [adverse effects]; 7. Rivastigmine [adverse effects];
MESH terms:
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
1. Bias; 2. *COVID-19; 3. *COVID-19 Drug Treatment; 4. Cytokines; 5. *Interleukin-6 [antagonists & inhibitors];
MESH terms:
Prebiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. *Enterocolitis, Necrotizing [etiology, prevention & control]; 2. Infant, Extremely Premature; 3. *Infant, Premature, Diseases [etiology, prevention & control]; 4. Infant, Very Low Birth Weight; 5. *Infections;
MESH terms:
Lactoferrin for the postoperative management of term neonates after gastrointestinal surgery
1. *Digestive System Surgical Procedures; 2. Infant, Premature; 3. Lactoferrin [therapeutic use]; 4. Milk; 5. *Sepsis [drug therapy, prevention & control];
MESH terms:
Videolaryngoscopy versus direct laryngoscopy for tracheal intubation in neonates
1. Intensive Care Units, Neonatal; 2. *Intubation, Intratracheal [adverse effects]; 3. *Laryngoscopy; 4. Resuscitation;
MESH terms:
Nasal high flow therapy for primary respiratory support in preterm infants
1. *Bronchopulmonary Dysplasia [prevention & control]; 2. Infant, Extremely Premature; 3. Oxygen; 4. *Pneumothorax [etiology]; 5. Respiration, Artificial [adverse effects]; 6. Surface-Active Agents;
MESH terms:
Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis
1. *Cystic Fibrosis [complications]; 2. Drainage, Postural [methods]; 3. Physical Therapy Modalities; 4. Quality of Life; 5. Respiratory Therapy [methods];
MESH terms:
Antiseptic solutions for skin preparation during central catheter insertion in neonates
1. *Anti-Infective Agents, Local [therapeutic use]; 2. *Burns, Chemical [drug therapy, etiology]; 3. *Central Venous Catheters [adverse effects]; 4. Chlorhexidine [adverse effects]; 5. *Sepsis [drug therapy];
MESH terms:
Personalised interventions for subgroups of children with conduct problems
1. Child Behavior; 2. Child Rearing; 3. Emotions; 4. Parents [psychology]; 5. *Problem Behavior; 6. United States;
MESH terms:
Fecal transplantation for treatment of inflammatory bowel disease
1. *Colitis, Ulcerative [drug therapy]; 2. *Crohn Disease [drug therapy]; 3. Dysbiosis; 4. Fecal Microbiota Transplantation; 5. *Inflammatory Bowel Diseases; 6. Quality of Life; 7. Remission Induction;
MESH terms:
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents
1. Amphetamine [therapeutic use]; 2. Atomoxetine Hydrochloride [therapeutic use]; 3. *Attention Deficit Disorder with Hyperactivity [drug therapy]; 4. *Fatty Acids, Omega-3 [therapeutic use]; 5. Fatty Acids, Unsaturated [therapeutic use]; 6. *Methylphenidate [therapeutic use]; 7. Quality of Life;
MESH terms:
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis
1. Cough [etiology]; 2. *Cystic Fibrosis [complications, therapy]; 3. Cystic Fibrosis Transmembrane Conductance Regulator; 4. Forced Expiratory Volume; 5. Radioactive Tracers;
MESH terms:
Systemic opioid regimens for postoperative pain in neonates
1. *Analgesia [methods]; 2. *Analgesics, Opioid [therapeutic use]; 3. Clinical Protocols; 4. Morphine [therapeutic use]; 5. Pain, Postoperative [drug therapy];
MESH terms:
Nebulised hypertonic saline solution for acute bronchiolitis in infants
1. *Bronchiolitis [drug therapy]; 2. *Bronchodilator Agents [therapeutic use]; 3. Cough; 4. Saline Solution [therapeutic use]; 5. Saline Solution, Hypertonic [therapeutic use];
MESH terms:
Non‐opioid analgesics for procedural pain in neonates
1. Analgesics [therapeutic use]; 2. *Analgesics, Non-Narcotic [therapeutic use]; 3. Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; 4. Apnea; 5. Body Weight; 6. Bradycardia [chemically induced]; 7. Fentanyl [therapeutic use]; 8. *Ketamine; 9. Pain [drug therapy, etiology]; 10. *Pain, Procedural [drug therapy, prevention & control]; 11. Receptors, N-Methyl-D-Aspartate [therapeutic use];
MESH terms:
Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old
1. *Bronchiolitis [drug therapy]; 2. Bronchodilator Agents [therapeutic use]; 3. Drainage, Postural; 4. Oxygen; 5. Physical Therapy Modalities; 6. *Respiratory Therapy [methods];
MESH terms:
Bubble devices versus other pressure sources for nasal continuous positive airway pressure in preterm infants
1. *Bronchopulmonary Dysplasia [epidemiology, etiology]; 2. Continuous Positive Airway Pressure [adverse effects, methods]; 3. Dyspnea; 4. Infant, Premature; 5. *Pneumothorax [epidemiology, etiology]; 6. *Respiratory Distress Syndrome;
MESH terms:
Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years
1. Diarrhea [chemically induced, epidemiology, prevention & control]; 2. Dietary Supplements; 3. Iron; 4. *Malaria; 5. *Malnutrition [prevention & control]; 6. Minerals; 7. Morbidity; 8. *Respiratory Tract Infections; 9. Zinc [therapeutic use];
MESH terms:
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
1. *Attention Deficit Disorder with Hyperactivity [drug therapy]; 2. *Central Nervous System Stimulants [adverse effects]; 3. Cross-Over Studies; 4. *Methylphenidate [adverse effects]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic;
MESH terms:
Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants
1. Cerebral Hemorrhage [chemically induced, prevention & control]; 2. *Hydrocephalus [complications, prevention & control]; 3. Infant, Premature; 4. *Infant, Premature, Diseases [etiology, prevention & control]; 5. Infant, Very Low Birth Weight; 6. Phenobarbital [therapeutic use];
MESH terms:
Botulinum toxin for the treatment of strabismus
1. *Botulinum Toxins [therapeutic use]; 2. Canada; 3. *Esotropia [drug therapy, surgery]; 4. *Strabismus [drug therapy, surgery];
MESH terms:
Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants
1. *Bronchopulmonary Dysplasia [prevention & control]; 2. *Cerebral Palsy [complications]; 3. Dexamethasone [adverse effects]; 4. Glucocorticoids [therapeutic use]; 5. Infant, Premature;
MESH terms:
Medical interventions for traumatic hyphema
1. Adrenal Cortex Hormones [therapeutic use]; 2. Aminocaproic Acid [therapeutic use]; 3. *Antifibrinolytic Agents [therapeutic use]; 4. Aspirin [therapeutic use]; 5. *Glaucoma [drug therapy]; 6. Hyphema [drug therapy, therapy]; 7. Mydriatics [therapeutic use]; 8. *Tranexamic Acid [therapeutic use];
MESH terms:
Ultrasound‐guided arterial cannulation in the paediatric population
1. *Arteries [diagnostic imaging]; 2. Catheterization; 3. *Hematoma; 4. Ultrasonography; 5. Ultrasonography, Interventional;
MESH terms:
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
1. Aminoglycosides; 2. Anti-Bacterial Agents; 3. *Codon, Nonsense; 4. *Cystic Fibrosis [drug therapy, genetics]; 5. Cystic Fibrosis Transmembrane Conductance Regulator [genetics]; 6. Mutation; 7. Persistent Infection;
MESH terms:
Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates
1. Acetaminophen; 2. Analgesics; 3. Analgesics, Opioid; 4. Cerebral Hemorrhage; 5. Fentanyl; 6. Morphine; 7. Pain, Postoperative; 8. *Retinopathy of Prematurity; 9. *Tramadol;
MESH terms:
Interventions for preventing and treating kidney disease in IgA vasculitis
1. Fosinopril; 2. *IgA Vasculitis [complications, drug therapy]; 3. *Kidney Diseases; 4. Leflunomide; 5. Proteinuria; 6. Tacrolimus; 7. *Vasculitis;
MESH terms:
Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients
1. Catheters; 2. Dialysis Solutions; 3. *Peritoneal Dialysis; 4. *Peritonitis; 5. Renal Dialysis;
MESH terms:
Probiotics for management of functional abdominal pain disorders in children
1. Abdominal Pain [therapy]; 2. Inulin; 3. *Irritable Bowel Syndrome; 4. *Probiotics [adverse effects]; 5. Treatment Outcome;
MESH terms:
Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants
1. *Cerebral Hemorrhage [prevention & control]; 2. Infant Mortality; 3. Infant, Extremely Premature; 4. *Infant, Premature, Diseases [etiology, prevention & control]; 5. Stem Cells;
MESH terms:
Antibiotics for chronic pulmonary infection in children with a neurodisability (neurodevelopmental disorder)
1. Anti-Bacterial Agents [therapeutic use]; 2. Hospitalization; 3. *Neurodevelopmental Disorders; 4. *Pneumonia [drug therapy]; 5. *Respiration Disorders;
MESH terms:
Behavioural and cognitive‐behavioural interventions for outwardly directed aggressive behaviour in people with intellectual disabilities
1. Aggression; 2. Cognition; 3. *Cognitive Behavioral Therapy [methods]; 4. *Intellectual Disability; 5. Quality of Life;
MESH terms:
Vitamin D for the management of asthma
1. Adrenal Cortex Hormones [adverse effects]; 2. *Anti-Asthmatic Agents [adverse effects]; 3. *Asthma [drug therapy]; 4. Calcifediol; 5. Cholecalciferol; 6. Disease Progression; 7. Hypercalciuria; 8. Randomized Controlled Trials as Topic; 9. Vitamin D [adverse effects]; 10. Vitamins [adverse effects];
MESH terms:
Active cycle of breathing technique for cystic fibrosis
1. *Chest Wall Oscillation; 2. *Cystic Fibrosis [therapy]; 3. Mucus; 4. Quality of Life; 5. Respiratory Therapy [methods];
MESH terms:
Physical interventions to interrupt or reduce the spread of respiratory viruses
1. *Communicable Disease Control [methods]; 2. COVID-19 [epidemiology, prevention & control]; 3. Global Health [statistics & numerical data]; 4. Influenza A Virus, H1N1 Subtype; 5. Influenza, Human [epidemiology, prevention & control]; 6. Randomized Controlled Trials as Topic; 7. *Respiratory Tract Infections [epidemiology, prevention & control]; 8. SARS-CoV-2;
MESH terms:
Surgical versus non‐surgical interventions for treating patellar dislocation
1. *Fractures, Bone; 2. Knee Joint; 3. Patella; 4. *Patellar Dislocation [surgery]; 5. Quality of Life;
MESH terms:
Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia
1. *Anti-Bacterial Agents [adverse effects, therapeutic use]; 2. *Community-Acquired Infections [complications, diagnosis, drug therapy]; 3. *Pneumonia [complications, diagnosis, drug therapy, prevention & control]; 4. *Vitamin D [administration & dosage, adverse effects, therapeutic use]; 5. *Vitamin D Deficiency [complications, drug therapy]; 6. Vitamins [administration & dosage, adverse effects, therapeutic use];
MESH terms:
Bisphosphonates for osteoporosis in people with cystic fibrosis
1. Alendronate [therapeutic use]; 2. *Bone Density Conservation Agents [adverse effects]; 3. *Cystic Fibrosis [complications, drug therapy]; 4. Diphosphonates [adverse effects]; 5. *Fractures, Bone [prevention & control]; 6. *Musculoskeletal Pain [chemically induced]; 7. *Osteoporosis [drug therapy]; 8. Pamidronate [therapeutic use]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. *Spinal Fractures; 12. Zoledronic Acid [therapeutic use];
MESH terms:
Glucocorticoids for croup in children
1. *Croup [drug therapy]; 2. Dexamethasone [therapeutic use]; 3. Epinephrine [therapeutic use]; 4. Glucocorticoids [therapeutic use]; 5. Prednisolone [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. *Respiratory Tract Infections;
MESH terms:
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
1. *Acetaminophen [adverse effects]; 2. Drug Therapy, Combination [adverse effects]; 3. *Ductus Arteriosus, Patent [drug therapy]; 4. Ibuprofen [therapeutic use]; 5. Indomethacin [therapeutic use]; 6. Infant, Low Birth Weight; 7. Infant, Premature; 8. Randomized Controlled Trials as Topic;
MESH terms:
Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
1. Adrenal Cortex Hormones [adverse effects]; 2. *Bronchopulmonary Dysplasia [etiology, prevention & control]; 3. Dexamethasone [therapeutic use]; 4. Glucocorticoids [therapeutic use]; 5. Infant, Premature; 6. Oxygen; 7. *Pneumonia [drug therapy];
MESH terms:
Vaccines for the common cold
1. *Adenovirus Vaccines [adverse effects]; 2. *Common Cold [prevention & control]; 3. Incidence; 4. Randomized Controlled Trials as Topic; 5. Systematic Reviews as Topic; 6. Vaccines, Attenuated [adverse effects];
MESH terms:
Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children
1. Anti-Bacterial Agents [therapeutic use]; 2. *Homeopathy [adverse effects]; 3. Intention to Treat Analysis; 4. Randomized Controlled Trials as Topic; 5. *Respiratory Tract Infections [drug therapy, prevention & control];
MESH terms:
Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
1. Anti-Bacterial Agents [therapeutic use]; 2. *Cystic Fibrosis [drug therapy]; 3. *Methicillin-Resistant Staphylococcus aureus; 4. Pseudomonas aeruginosa; 5. Rifampin [therapeutic use];
MESH terms:
Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services
1. *Child Rearing; 2. Health Services; 3. *Parenting; 4. Parents; 5. Primary Health Care;
MESH terms:
Ultrasound guidance versus landmark method for peripheral venous cannulation in adults
1. *Catheterization, Central Venous [methods]; 2. *Catheterization, Peripheral [adverse effects]; 3. Pain; 4. Randomized Controlled Trials as Topic;
MESH terms:
Bioengineered nerve conduits and wraps for peripheral nerve repair of the upper limb
1. *Peripheral Nerves [surgery]; 2. *Upper Extremity [surgery];
MESH terms:
Statins for Smith‐Lemli‐Opitz syndrome
1. Bile Acids and Salts; 2. Cholesterol; 3. Cross-Over Studies; 4. *Hydroxymethylglutaryl-CoA Reductase Inhibitors [adverse effects]; 5. Randomized Controlled Trials as Topic; 6. *Smith-Lemli-Opitz Syndrome [drug therapy]; 7. Vitamins;
MESH terms:
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
1. Anti-Bacterial Agents [therapeutic use]; 2. Aztreonam [therapeutic use]; 3. *Cystic Fibrosis [complications, drug therapy, microbiology]; 4. Lysine [therapeutic use]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Tobramycin [therapeutic use];
MESH terms:
Pharmacological interventions for pain and sedation management in newborn infants undergoing therapeutic hypothermia
1. Clonidine [therapeutic use]; 2. *Dexmedetomidine [therapeutic use]; 3. *Hypothermia, Induced; 4. Morphine Derivatives; 5. Observational Studies as Topic; 6. Pain [drug therapy, etiology];
MESH terms:
Support for healthy breastfeeding mothers with healthy term babies
1. Breast Feeding; 2. Diet; 3. *Maternal Health Services; 4. Mothers [psychology]; 5. Telephone;
MESH terms:
Biomarkers as point‐of‐care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care
1. *Anti-Bacterial Agents [therapeutic use]; 2. Biomarkers; 3. C-Reactive Protein [analysis]; 4. Inflammation; 5. Point-of-Care Testing; 6. Prescriptions; 7. Primary Health Care; 8. Procalcitonin [therapeutic use]; 9. Randomized Controlled Trials as Topic; 10. *Respiratory Tract Infections [diagnosis, drug therapy];
MESH terms:
Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis‐associated uveitis
1. Adalimumab [adverse effects]; 2. *Arthritis, Juvenile [complications, drug therapy]; 3. Etanercept [adverse effects]; 4. Tumor Necrosis Factor Inhibitors [adverse effects]; 5. Tumor Necrosis Factor-alpha; 6. *Uveitis [drug therapy, etiology];
MESH terms:
Splinting for the non‐operative management of developmental dysplasia of the hip (DDH) in children under six months of age
1. Bias; 2. *Developmental Dysplasia of the Hip; 3. Mothers; 4. Necrosis; 5. Parents;
MESH terms:
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children
1. Adrenal Cortex Hormones [therapeutic use]; 2. *Anti-Asthmatic Agents; 3. *Asthma [drug therapy]; 4. Hospitalization; 5. Nebulizers and Vaporizers; 6. Randomized Controlled Trials as Topic;
MESH terms:
Laser therapy for treating hypertrophic and keloid scars
1. Adrenal Cortex Hormones [therapeutic use]; 2. Aluminum; 3. Atrophy; 4. Carbon Dioxide; 5. *Cicatrix, Hypertrophic [etiology, radiotherapy]; 6. Dimethylpolysiloxanes; 7. Erbium; 8. Fluorouracil; 9. Helium; 10. Hypertrophy; 11. *Hypopigmentation [etiology]; 12. *Keloid [etiology, radiotherapy]; 13. *Laser Therapy [adverse effects]; 14. Neodymium; 15. Neon; 16. Pain [etiology]; 17. Silicone Gels; 18. *Telangiectasis [etiology]; 19. Triamcinolone Acetonide; 20. Verapamil; 21. Wound Healing; 22. Yttrium;
MESH terms:
Appetite stimulants for people with cystic fibrosis
1. Anorexia [chemically induced, drug therapy]; 2. Anti-Bacterial Agents [therapeutic use]; 3. Appetite Stimulants [therapeutic use]; 4. Cyproheptadine [therapeutic use]; 5. *Cystic Fibrosis [complications, drug therapy, genetics]; 6. Megestrol Acetate [therapeutic use]; 7. Quality of Life;
MESH terms:
Synbiotics, prebiotics and probiotics for solid organ transplant recipients
1. Albumins; 2. Anti-Bacterial Agents [therapeutic use]; 3. *Cardiovascular Diseases; 4. Dysbiosis; 5. Endotoxins; 6. Lipids; 7. *Organ Transplantation; 8. Prebiotics; 9. *Probiotics [therapeutic use]; 10. *Synbiotics;
MESH terms:
Fluvoxamine for the treatment of COVID‐19
1. *Clinical Deterioration; 2. *COVID-19 Drug Treatment; 3. Fluvoxamine [pharmacology, therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Selective Serotonin Reuptake Inhibitors [therapeutic use];
MESH terms:
Water for wound cleansing
1. *Drinking Water; 2. *Fractures, Open; 3. Pain [drug therapy]; 4. Saline Solution; 5. Sodium Chloride [therapeutic use]; 6. Therapeutic Irrigation [methods]; 7. *Wound Infection [prevention & control];
MESH terms:
Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients
1. Graft Rejection [drug therapy, prevention & control]; 2. *Immunosuppressive Agents [adverse effects]; 3. Medication Adherence; 4. *Organ Transplantation; 5. Transplant Recipients;
MESH terms:
Adding rapid diagnostic tests to community‐based programmes for treating malaria
1. Anti-Bacterial Agents [therapeutic use]; 2. *Antimalarials [therapeutic use]; 3. Cross-Over Studies; 4. Diagnostic Tests, Routine [methods]; 5. *Malaria [diagnosis, drug therapy, epidemiology];
MESH terms:
Stiripentol add‐on therapy for drug‐resistant focal epilepsy
1. Anticonvulsants [adverse effects]; 2. *Dioxolanes [adverse effects]; 3. *Drug Resistant Epilepsy [drug therapy]; 4. Drug Therapy, Combination; 5. *Epilepsies, Partial [drug therapy]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Seizures [drug therapy];
MESH terms:
D‐mannose for preventing and treating urinary tract infections
1. Anti-Bacterial Agents [therapeutic use]; 2. *Bacteriuria [drug therapy]; 3. Kidney; 4. Mannose [therapeutic use]; 5. *Urinary Tract Infections [drug therapy, prevention & control];